Stock Analysis

European Stocks That May Be Trading Below Their Estimated Intrinsic Value

OM:BIOT
Source: Shutterstock

In recent weeks, the European stock market has exhibited cautious optimism, with the pan-European STOXX Europe 600 Index experiencing a modest rise amid ongoing geopolitical developments and economic challenges. As investors navigate these uncertain waters, identifying stocks that may be trading below their estimated intrinsic value can offer potential opportunities for those looking to capitalize on undervaluation in the market.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

NameCurrent PriceFair Value (Est)Discount (Est)
Vimi Fasteners (BIT:VIM)€0.995€1.9548.9%
Wienerberger (WBAG:WIE)€33.62€67.1349.9%
CD Projekt (WSE:CDR)PLN222.90PLN441.9549.6%
Vestas Wind Systems (CPSE:VWS)DKK104.05DKK205.0749.3%
Nyab (OM:NYAB)SEK5.27SEK10.4249.4%
Cint Group (OM:CINT)SEK6.67SEK13.2249.5%
Surgical Science Sweden (OM:SUS)SEK159.00SEK310.4248.8%
Groupe Airwell Société anonyme (ENXTPA:ALAIR)€1.24€2.4248.7%
Bactiguard Holding (OM:BACTI B)SEK34.80SEK68.9749.5%
Facephi Biometria (BME:FACE)€2.07€4.0448.7%

Click here to see the full list of 201 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Biotage (OM:BIOT)

Overview: Biotage AB (publ) offers solutions and products for drug discovery and development, analytical testing, and water and environmental testing, with a market cap of approximately SEK9.29 billion.

Operations: The company generates revenue from its Healthcare Software segment, amounting to SEK2.06 billion.

Estimated Discount To Fair Value: 39.9%

Biotage, trading at SEK116, is significantly undervalued compared to its estimated fair value of SEK192.89, offering a potential opportunity for investors focused on cash flow valuation. Despite slower revenue growth forecasts (9.7% annually) than the ideal 20%, it surpasses the Swedish market's 0.9% growth rate and boasts impressive expected earnings growth of over 20% annually. Recent financials show net income increased to SEK284 million in 2024 from SEK246 million in 2023, alongside a proposed dividend increase to SEK1.65 per share for 2024.

OM:BIOT Discounted Cash Flow as at Feb 2025
OM:BIOT Discounted Cash Flow as at Feb 2025

Comet Holding (SWX:COTN)

Overview: Comet Holding AG, along with its subsidiaries, offers X-ray and radio frequency power technology solutions across Europe, North America, Asia, and other international markets, with a market cap of CHF2.15 billion.

Operations: The company's revenue segments include X-Ray Systems at CHF115.34 million, Industrial X-Ray Modules at CHF95.90 million, and Plasma Control Technologies at CHF180.62 million.

Estimated Discount To Fair Value: 36.5%

Comet Holding, trading at CHF276, is significantly undervalued with a fair value estimate of CHF434.38, presenting a potential opportunity for cash flow-focused investors. Despite recent profit margin declines to 4.6% from 10.8%, earnings are projected to grow substantially at 48.54% annually over the next three years—outpacing the Swiss market's growth rate of 11.4%. However, its share price has been highly volatile recently, adding an element of risk.

SWX:COTN Discounted Cash Flow as at Feb 2025
SWX:COTN Discounted Cash Flow as at Feb 2025

Stadler Rail (SWX:SRAIL)

Overview: Stadler Rail AG, with a market cap of CHF2.11 billion, manufactures and sells trains across Switzerland, Germany, Austria, various parts of Europe, the Americas, and the CIS countries.

Operations: The company's revenue segments include CHF135.68 million from Signalling, CHF3.10 billion from Rolling Stock, and CHF789.41 million from Service & Components.

Estimated Discount To Fair Value: 40.9%

Stadler Rail, currently trading at CHF21.1, is undervalued with a fair value estimate of CHF35.68, offering potential for cash flow-focused investors. While its Return on Equity is forecast to be low at 18.7% in three years, earnings are expected to grow significantly by 22.94% annually, outpacing the Swiss market's growth rate of 11.4%. Despite this growth potential, its dividend yield of 4.27% isn't well covered by free cash flows.

SWX:SRAIL Discounted Cash Flow as at Feb 2025
SWX:SRAIL Discounted Cash Flow as at Feb 2025

Seize The Opportunity

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Biotage might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com